Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
3.810
+0.030 (0.79%)
Aug 6, 2026, 9:43 AM EDT - Market open
Opus Genetics Employees
As of December 31, 2025, Opus Genetics had 28 total employees, including 27 full-time and 1 part-time employees. The number of employees increased by 10 or 55.56% compared to the previous year.
Employees
28
Change (1Y)
10
Growth (1Y)
55.56%
Revenue / Employee
$427,964
Profits / Employee
-$3,819,000
Market Cap
314.58M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 28 | 10 | 55.56% | 27 | 1 |
| Dec 31, 2024 | 18 | 4 | 28.57% | 18 | 0 |
| Dec 31, 2023 | 14 | 5 | 55.56% | 14 | 0 |
| Dec 31, 2022 | 9 | 1 | 12.50% | 9 | 0 |
| Dec 31, 2021 | 8 | 3 | 60.00% | 8 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Fate Therapeutics | 161 |
| Lyell Immunopharma | 161 |
| Neumora Therapeutics | 92 |
| OmniAb | 89 |
| SAB Biotherapeutics | 86 |
| Vicore Pharma Holding AB | 40 |
| Anavex Life Sciences | 34 |
IRD News
- 2 hours ago - Opus Genetics reports Q2 EPS (14c), consensus (16c) - TheFly
- 2 hours ago - Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update - GlobeNewsWire
- 2 hours ago - Opus Genetics Earnings release: Q2 2026 - Filings
- 3 days ago - Opus Genetics enrolls last patient in OPGx-LCA5 trial - TheFly
- 3 days ago - Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease - GlobeNewsWire
- 8 days ago - Opus Genetics initiated with a Buy at TD Cowen - TheFly
- 4 weeks ago - Opus Genetics sets September timeline for retinal disease trial data - TheFly
- 4 weeks ago - Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results - GlobeNewsWire